Theriva Biologics Receives FDA Fast Track Designation For VCN-01 In Combination With Gemcitabine And Nab-Paclitaxel To Improve Survival In Metastatic Pancreatic Adenocarcinoma
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics has received FDA Fast Track Designation for its VCN-01 therapy in combination with Gemcitabine and Nab-Paclitaxel to improve survival in metastatic pancreatic adenocarcinoma.
May 23, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Theriva Biologics has received FDA Fast Track Designation for its VCN-01 therapy in combination with Gemcitabine and Nab-Paclitaxel to improve survival in metastatic pancreatic adenocarcinoma.
The FDA Fast Track Designation is a significant regulatory milestone that can expedite the development and review process of VCN-01. This increases the likelihood of the therapy reaching the market sooner, which is positive news for Theriva Biologics.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100